title: Radioprotective effect of montelukast sodium in rat lacrimal glands after radioiodine treatment.
abstract: OBJECTIVE
  The aim of this study was to evaluate the morphological changes of rat lacrimal glands at the third month following radioiodine (RAI) treatment and the radioprotective effect of montelukast (ML) sodium against RAI-related lacrimal gland damage.
  
  
  METHODS
  Fifty female Wistar Albino rats were divided into three groups. The control group (n=10) consisted of rats with no intervention. RAI group (n=20) consisted of rats treated with oral (131)I (111 MBq). The ML group (n=20) consisted of rats treated with intraperitoneal 10mg/kg/day ML sodium, starting three days before and continuing for one week after oral RAI administration. Intraorbital (IG), extraorbital (EG) and Harderian glands (HG) were removed bilaterally after three months.
  
  
  RESULTS
  The existence of acinar atrophy, acinar fibrosis, abnormal cell lines, peripheral basophilia, cell size variation and decrease in amount of cytoplasm was significantly more common in the RAI-rat treated group than in the ML group, in each of the glands. The ML-treated group had less-frequent cell shape variation in EG (P=0.001) and HG (P=0.027), cell size variation in IG (P<0.001) and HG (P=0.01), ductal pathology in EG (P<0.001) and HG (P<0.001) and lipofuscin accumulation in EG (P=0.001) and in HG (P=0.01) than the RAI-treated group.
  
  
  CONCLUSIONS
  RAI treatment seems to cause morphological damage to rat lacrimal glands, and ML sodium effectively protects against damage to lacrimal glands.
authors.affiliation: Department of Nuclear Medicine, Ankara Training and Research Hospital, Ministry of Health, Ankara, Turkey.
authors.forename: G
authors.initials: G
authors.lastname: Koca
authors.forename: Z
authors.initials: Z
authors.lastname: Yalniz-Akkaya
authors.forename: S S
authors.initials: SS
authors.lastname: Gültekin
authors.forename: N
authors.initials: N
authors.lastname: Yumusak
authors.forename: K
authors.initials: K
authors.lastname: Demirel
authors.forename: M
authors.initials: M
authors.lastname: Korkmaz
authors.forename: H I
authors.initials: HI
authors.lastname: Atilgan
authors.forename: U E
authors.initials: UE
authors.lastname: Altiparmak
authors.forename: B
authors.initials: B
authors.lastname: Onal
authors.forename: F
authors.initials: F
authors.lastname: Ornek
mesh_terms: D000085:Acetates / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D001284:Atrophy; D003521:Cyclopropanes; D004353:Drug Evaluation, Preclinical; D005260:Female; D005355:Fibrosis; D007274:Injections, Intraperitoneal; D007457:Iodine Radioisotopes / Q000633:toxicity*; D007765:Lacrimal Apparatus / Q000187:drug effects* / Q000528:radiation effects / Q000648:ultrastructure; D020556:Neutrophil Infiltration; D018384:Oxidative Stress; D011804:Quinolines / Q000008:administration & dosage / Q000627:therapeutic use*; D011833:Radiation Injuries, Experimental / Q000209:etiology / Q000517:prevention & control*; D011837:Radiation-Protective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D013440:Sulfides; D013961:Thyroid Gland / Q000473:pathology / Q000528:radiation effects
chemical_list: D000085:Acetates; D003521:Cyclopropanes; D007457:Iodine Radioisotopes; D011804:Quinolines; D011837:Radiation-Protective Agents; D013440:Sulfides; C093875:montelukast
keywords: Agente radioprotector; Glándula lagrimal; Lacrimal gland; Montelukast sodium; Montelukast sódico; Radioiodine-131; Radioprotección; Radioprotection; Radioprotective agent; Rat; Rata; Yodo radiactivo